Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Aus… Read more
Argenica Therapeutics Ltd (AGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -1.602x
Based on the latest financial reports, Argenica Therapeutics Ltd (AGN) has a cash flow conversion efficiency ratio of -1.602x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.51 Million) by net assets (AU$3.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Argenica Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Argenica Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Argenica Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Argenica Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jade Gas Holdings Ltd
AU:JGH
|
-0.048x |
|
Sat Nusapersada Tbk
JK:PTSN
|
0.036x |
|
Twenty-Four Con & Supply PCL
BK:24CS
|
0.042x |
|
Merck Tbk
JK:MERK
|
0.165x |
|
MFC-Strategic Storage Fund
BK:M-STOR
|
0.012x |
|
Nordic Paper Holding AB
ST:NPAPER
|
0.115x |
|
TOWER RESOURCES LS-00001
F:ULF1
|
N/A |
|
Juic International
TWO:6114
|
-0.125x |
Annual Cash Flow Conversion Efficiency for Argenica Therapeutics Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Argenica Therapeutics Ltd from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$7.24 Million | AU$-5.70 Million | -0.788x | -117.29% |
| 2023-12-31 | AU$13.95 Million | AU$-5.06 Million | -0.363x | +15.74% |
| 2022-12-31 | AU$7.67 Million | AU$-3.30 Million | -0.430x | -6.38% |
| 2021-12-31 | AU$8.31 Million | AU$-3.36 Million | -0.405x | -164.77% |
| 2020-12-31 | AU$6.85 Million | AU$-1.05 Million | -0.153x | +95.22% |
| 2019-12-31 | AU$18.40K | AU$-58.82K | -3.197x | -- |